Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Business Progress: Q3 revenues and earnings down Y/Y due to weaker academic/research instruments demand, but better than expected and sequential improvement from Q2. Mid-single-digit organic bookings growth, strength in academic government and biopharma/applied markets. ACA/GOV orders up high teens in Q3 with international offsetting US softness. New spatial biology, proteomics, multiomics solutions well received by customers.
• Financials: Q3 '25 reported revenues $860.5M (-0.5% Y/Y, +2.9% currency tailwind), organic revenue down 4.5%, non-GAAP operating margin 12.3% (down 260 bps Y/Y). YTD '25 revenue $2.5B (+3.0% Y/Y), organic revenue down 3.1%.
• Cost Savings: Major cost savings initiatives on track towards $100M-$120M cost down targets for 2026, expected to drive margin expansion and double-digit EPS growth in 2026.

Segment Performance

• Scientific Instruments Group:
  • BioSpin Group CER: Revenue of $612 million, down mid-single digits. Saw growth in lab automation and services, but offset by tough comp from 2 GigaHertz class NMR systems in Q3 '24. Improved order growth in ACA/GOV and biopharma in Q3 '25.
  • CALID Group: Revenue of $879 million, increased in low double-digit percentage, driven by microbiology and infectious disease diagnostics, with strength in MALDI Biotyper and ELITech molecular diagnostics franchises. Life science mass spectrometry seeing early traction for new products.
  • Bruker Nano: Revenue of $775 million, declined in low single-digit percentage. Advanced X-ray and Nano analysis tools down year-over-year, partially offset by growth in spatial biology. Strength in biopharma offset by weakness in ACA/GOV and softer industrial research/semi markets.
• BEST Segment: Revenues declined in mid-single-digit percentage net of intercompany eliminations. Clinical MRI superconducting wire market improved in Q3 and flat YTD, while BEST research instruments weaker due to strong prior year comparison.

Guidance

• Full-Year 2025: Revenue range $3.41B-$3.44B, organic decline 4%-5%, acquisitions contribute ~3.5%, foreign currency tailwind ~2.5%, reported revenue growth 1%-2%. Operating margin expected to decline ~250 bps Y/Y. Non-GAAP EPS range $1.85-$1.90 (includes $0.07 dilution from mandatory convertible preferred offering).
• Q4 2025: Expected relatively soft organic revenue performance with mid- to high single-digit percentage decline Y/Y, but non-GAAP EPS to show significant sequential improvement.
• 2026: Expect significant margin expansion and double-digit EPS growth, with cost savings initiatives driving improvement even in flat revenue scenarios.

Risks

• Geopolitical/Market Risks: Geopolitical risks, tariffs, foreign currency, market demand or supply chains.
• Government Shutdown Impact: Potential delay in grants, orders, or installations if shutdown continues, not formally baked into guidance but could have additional impacts if prolonged.
• Order Timing: Late order bookings and customer site delays impacting revenue recognition and guidance.

Question and Answer

• Q: Puneet Souda on book-to-bill and Q4 momentum A: Frank Laukien said no meaningful Q4 data yet, ACA/GOV orders strength primarily outside US, US ACA/GOV orders less soft in Q3 vs Q2, biopharma and applied market strength broad internationally, too early to comment on Q4 trend.
• Q: Avantika Dhabaria on govt shutdown impact A: Frank Laukien said not formally baked into outlook, assumed minor effect so far, but further multi-week/month shutdown could delay grants/orders/installations.
• Q: Tycho Peterson on margin expansion and China stimulus A: Frank Laukien said driving towards high end of cost savings target for increased confidence in margin expansion and double-digit EPS growth; China had some green shoots with stimulus-related orders, but less than $10M, need to see Q4 bookings for clarity.
• Q: Casey Woodring on backlog A: Gerald Herman said current backlog ~7 months (up from 6.5 months Q2), depends on 2026 revenue performance, still carry considerable backlog into 2026.